Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania
You may also be interested in...
Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
TOKYO - In what is being called the first formidable entry into the African market by a leading pharmaceutical group, Daiichi Sankyo and its Indian generic subsidiary Ranbaxy announced Dec. 22 they will jointly launch Daiichi's proprietary hypertension treatment Olvance (olmesartan) in the six countries of Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia
Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
TOKYO - In what is being called the first formidable entry into the African market by a leading pharmaceutical group, Daiichi Sankyo and its Indian generic subsidiary Ranbaxy announced Dec. 22 they will jointly launch Daiichi's proprietary hypertension treatment Olvance (olmesartan) in the six countries of Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change